ALUR vs. IRIX, DRIO, XAIR, PTHL, CODX, BSGM, FEMY, NXGL, VVOS, and PETV
Should you be buying Allurion Technologies stock or one of its competitors? The main competitors of Allurion Technologies include IRIDEX (IRIX), DarioHealth (DRIO), Beyond Air (XAIR), Pheton Holdings Ltd Class A Ordinary Shares (PTHL), Co-Diagnostics (CODX), BioSig Technologies (BSGM), Femasys (FEMY), NEXGEL (NXGL), Vivos Therapeutics (VVOS), and PetVivo (PETV). These companies are all part of the "medical equipment" industry.
Allurion Technologies vs.
Allurion Technologies (NYSE:ALUR) and IRIDEX (NASDAQ:IRIX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.
IRIDEX received 265 more outperform votes than Allurion Technologies when rated by MarketBeat users. However, 87.50% of users gave Allurion Technologies an outperform vote while only 64.30% of users gave IRIDEX an outperform vote.
Allurion Technologies has a beta of -0.62, suggesting that its stock price is 162% less volatile than the S&P 500. Comparatively, IRIDEX has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.
In the previous week, Allurion Technologies had 7 more articles in the media than IRIDEX. MarketBeat recorded 8 mentions for Allurion Technologies and 1 mentions for IRIDEX. Allurion Technologies' average media sentiment score of 0.50 beat IRIDEX's score of 0.00 indicating that Allurion Technologies is being referred to more favorably in the media.
Allurion Technologies presently has a consensus price target of $71.88, indicating a potential upside of 2,566.98%. IRIDEX has a consensus price target of $2.00, indicating a potential upside of 20.48%. Given Allurion Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe Allurion Technologies is more favorable than IRIDEX.
IRIDEX has a net margin of -22.79% compared to Allurion Technologies' net margin of -71.24%. Allurion Technologies' return on equity of 0.00% beat IRIDEX's return on equity.
21.4% of Allurion Technologies shares are owned by institutional investors. Comparatively, 20.1% of IRIDEX shares are owned by institutional investors. 22.4% of Allurion Technologies shares are owned by insiders. Comparatively, 7.3% of IRIDEX shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
IRIDEX has lower revenue, but higher earnings than Allurion Technologies. IRIDEX is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
Allurion Technologies beats IRIDEX on 12 of the 19 factors compared between the two stocks.
Get Allurion Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALUR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allurion Technologies Competitors List
Related Companies and Tools
This page (NYSE:ALUR) was last updated on 1/21/2025 by MarketBeat.com Staff
